News + Stories News + Stories Target ALS Announces Second Round of 2020 Grant Recipients Focused on Discovering and Developing ALS Biomarkers READ MORE Target ALS Launches The First-Ever Comprehensive Research Initiative to Discover Urgently Needed ALS Biomarkers READ MORE Research Funding Decisions Made Fair; Independent Review is Key READ MORE We Salute You: Tom’s Life Was Defined By Much, But Not By ALS READ MORE Tripper’s Five Tips to Take on “The Toughest Challenge” in Support of ALS Research READ MORE ALS Charity Gets Creative During COVID-19 By Taking On ‘The Toughest Challenge’ READ MORE Under The Microscope: The Role of Genomics in ALS Research READ MORE Meet The Toughest Challenge For The Hardest Fight / Join Us to Make a Difference READ MORE 5 Answers About ALS From Our CEO READ MORE Our ROI: Impact to Date of the Target ALS Innovation Ecosystem READ MORE ‘The Unexpected Artist’: Guest Post by Ron Hoffman, Compassionate Care ALS Founder READ MORE ‘Never Say Invisible’: One Family’s Perspective on Living with ALS READ MORE UNDER THE MICROSCOPE: Why TDP-43 Matters So Much in ALS Research READ MORE Under the Microscope: Sophie Parmentier-Batteur on Interrogating a Protein Compound for Possible Therapeutic Approaches to ALS and FTD READ MORE UNDER THE MICROSCOPE: Ludo Van Den Bosch on Returning to Work, Exploring Therapeutic Strategies to Battle ALS & FTD READ MORE Searching for Information, a Media Resource Offers Credible, Compassionate News and Relatable Stories to the ALS Community READ MORE Under the Microscope: Fen-Biao Gao ofUMass Medical School Explains His Now-Funded Project Targeting Biomarkers and Disease Modifiers for ALS and FTD READ MORE Building a Safer Future: How Matt’s Place Foundation is Helping ALS Patients With Home Accessibility READ MORE Target ALS and AFTD Announce $5MM in Grants for Research Targeting Treatments and Biomarkers READ MORE Target ALS and The ALS Association Announce New TDP-43-Focused Biomarker Initiative READ MORE Target ALS Annual Meeting Canceled Due to the Spread of COVID-19 READ MORE Target ALS Expands Stem Cell Core to Include Innovative New Reporter Lines READ MORE What’s Next for Target ALS? A Preview of Our Work in 2020 READ MORE Thanks to Your Support: $35 Million Raised in 2019 READ MORE Target ALS Innovation Ecosystem Impact & Upcoming Initiatives READ MORE ALS/FTD Response Signals Resounding Desire for Collaboration READ MORE A Cancer Drug for ALS? Organization Forges Promising ALS Treatment, an Innovative Approach to Incubate Novel Therapeutics READ MORE NEWS: Target ALS-Funded Research Shows Promise in Slowing ALS Disease Progression Scientists Discover Method to Decrease Neuroinflammation and Extend Life Expectancy READ MORE 150 Years Later, Still No Effective Treatment for ALS. New Research Model Offers Hope READ MORE NEWS: Target ALS Biosample Recipients Identify Three Distinct Subtypes of ALS READ MORE Target ALS & AFTD Announce Groundbreaking Partnership to Spur Drug and Biomarker Development for ALS and FTD READ MORE The Boston Globe Features Target ALS Founder, Dan Doctoroff READ MORE Target ALS Awards Six Innovative Research Teams with Additional Target Discovery Funds READ MORE American Academy of Neurology and Target ALS Partner to Accelerate ALS Research READ MORE Case Study: Collaboration Accelerates Potential ALS Treatment READ MORE Case Study: Consortium Explores KPT-350 as a Potential Treatment for ALS READ MORE Target ALS Foundation Makes Human Stem Cell Lines Accessible to Researchers READ MORE Target ALS Providing Critical Tool to Study C9ORF72 Biology READ MORE Case Study: Biomarkers Offer Optimism for People with ALS READ MORE New Biomarker Study with Academic, Industry and Philanthropic Partners READ MORE Target ALS expands core facilities access to MDA development grant awardees READ MORE Target ALS Foundation Selects RUCDR Infinite Biologics READ MORE Partnership to Uncover Connection Between Ancient Retroviruses and ALS READ MORE Biogen and Target ALS Foundation Announce $20 Million Funding Challenge READ MORE The New York Times Features Daniel L. Doctoroff, Target ALS Founder READ MORE